NGNE
Neurogene Inc.
$39.63
-3.21
(-7.49%)
Mkt Cap
626.25M
Volume
290,555
52W Range
15.93-43.66
Sector
Healthcare
Beta
1.96
EPS (TTM)
-5.03
P/E Ratio
-4.86
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 925,000 | 0 | 0 | 0 | 0 | 0 | 25.00M | 0 | 0 | 0 | 0 |
| Net Income | (90.35M) | (75.14M) | (36.32M) | (55.19M) | (50.52M) | (33.28M) | (69.44M) | (31.59M) | (50.18M) | (37.00M) | (21.86M) | (23.82M) |
| EPS | -4.24 | -4.28 | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 |
| Free Cash Flow | (78.36M) | (71.41M) | (51.74M) | (55.05M) | (64.77M) | (26.79M) | (16.27M) | (31.63M) | (45.21M) | (30.94M) | (20.30M) | (17.92M) |
| FCF / Share | -3.70 | -4.07 | -4.03 | -4.29 | -1.18 | -0.52 | -0.60 | -1.34 | -1.93 | -1.64 | -1.61 | -2.07 |
| Operating CF | (77.17M) | (70.60M) | (51.42M) | (52.82M) | (46.40M) | (24.57M) | (15.39M) | (31.58M) | (44.72M) | (30.23M) | (20.27M) | (17.81M) |
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M | 210.52M | 147.02M | 77.62M | 110.33M | 154.38M | 113.34M | 41.42M |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M | 12.12M | 1.21M | 5,999 | 32,999 | 47,000 | 131,000 | 72,341 |
| Cash & Equiv | 103.84M | 136.59M | 148.21M | 82.02M | 70.54M | 192.56M | 143.09M | 76.93M | 52.03M | 32.30M | 39.53M | 14.91M |
| Book Value | 264.89M | 310.38M | 186.02M | 98.63M | (91.88M) | 191.22M | 141.69M | 72.67M | 98.89M | 144.66M | 108.42M | 36.15M |
| Return on Equity | -0.34 | -0.24 | -0.20 | -0.56 | N/A | -0.17 | -0.49 | -0.43 | -0.51 | -0.26 | -0.20 | -0.66 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925,000 | 0 | 0 | 0 | 0 |
| Net Income | (30.93M) | (24.73M) | (20.95M) | (22.02M) | (22.65M) | (19.51M) | (20.22M) | (18.49M) | (16.92M) | 2.38M | (14.58M) | (11.86M) |
| EPS | -1.39 | -1.60 | -0.99 | -1.05 | -1.08 | -1.31 | -1.19 | -1.09 | -1.00 | -1.21 | -0.41 | -0.21 |
| Free Cash Flow | (26.40M) | (16.79M) | (19.81M) | (19.61M) | (21.55M) | (17.61M) | (15.73M) | (16.35M) | (21.71M) | (29.28M) | (11.65M) | (9.41M) |
| FCF / Share | -1.18 | -1.08 | -0.94 | -0.93 | -1.03 | -1.19 | -0.93 | -0.97 | -1.28 | -2.28 | -1.05 | -0.17 |
| Operating CF | (26.12M) | (16.67M) | (19.68M) | (19.46M) | (20.77M) | (17.50M) | (15.56M) | (15.89M) | (21.65M) | (29.52M) | (11.57M) | (9.33M) |
| Total Assets | 263.14M | 289.18M | 287.83M | 297.32M | 315.30M | 335.73M | 164.12M | 179.82M | 195.35M | 222.57M | 89.59M | 85.79M |
| Total Debt | 9.13M | 9.89M | 11.27M | 12.85M | 13.54M | 12.43M | 14.53M | 13.79M | 14.41M | 16.25M | 11.47M | 4.39M |
| Cash & Equiv | 124.16M | 103.84M | 71.00M | 58.81M | 70.77M | 136.59M | 66.63M | 111.03M | 150.14M | 148.21M | 25.23M | 59.05M |
| Book Value | 237.78M | 264.89M | 265.54M | 273.25M | 291.80M | 310.38M | 137.41M | 155.01M | 170.78M | 186.02M | 75.23M | (169.05M) |
| Return on Equity | -0.13 | -0.09 | -0.08 | -0.08 | -0.08 | -0.06 | -0.15 | -0.12 | -0.10 | 0.01 | -0.19 | N/A |
NGNE News
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Neurogene Inc. Announces Proposed Public Offering
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates